Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone

Diabetes

Volumn 48, Issue 4, 1999, Pages 783-790

  Crawford, Richard S ^a   Mudaliar, Sunder R ^b   Henry, Robert R ^b   Chait, Alan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBUCOL; TROGLITAZONE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; GLUCOSE HOMEOSTASIS; HUMAN; LIPID OXIDATION; LIPID TRANSPORT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032998651     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.4.783     Document Type: Article

References (49)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
2. Lyons TJ: Oxidized low-density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes. Diabetes Med 8:411-419, 1991
3. Tsai EC, Hirsch IB, Brunzell JD, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43: 1010-1014, 1994
4. Morel DW, Hessler JR, Chisolm GM: Low-density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 24:1070-1076, 1983
5. Berliner JA Territo MC, Sevanian A, Romin S, Kim JA, Bamshad B, Esterson M, Kogelman AM: Minimally modified LDL stimulates monocyte endothelial interactions. J Clin Invest 85:1260-1266, 1990
6. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low-density lipoproteins. Proc Natl Acad Sci U S A 78:6499-6503, 1981
7. Hamilton TA, Ma GP, Chisolm GM: Oxidized low-density lipoprotein suppresses the expression of tumor necrosis factor-alpha mRNA in stimulated murine peritoneal macrophages. J Immunol 144:2343-2350, 1990
8. Malden LT, Chait A, Raines EW, Ross R: The influence of oxidatively modified lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J Biol Chem 25:13901-13907, 1991
9. Latron Y, Chautan M, Anfosso I, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I: Stimulatory effect of oxidized low-density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 11:1821-1829, 1991
10. Reaven PD, Khouw A, Beltz, WF, Parthasarathy S, Witztum JL: Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not by β-carotene. Arterioscler Thromb 13:590-600, 1993
11. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D: Probucol inhibits oxidative modification of low-density lipoprotein. J Clin Invest 77:641-644, 1980
12. Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that the antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL) rabbit. Proc Natl Acad Sci U S A 84:7725-7729, 1987
13. Chang MY, Sasahara M, Chait A, Raines EW, Ross R: Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate 1 by probucol. II. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 10:1631-1640, 1995
14. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ: Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 94:153-159, 1992
15. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kimiakura S, Inooka G, Shiraishi E: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1085-1086, 1991
16. Lee MK, Olefsky JM: Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44:1106-1169, 1995
17. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320, 1995
18. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulfonylureas in patients with type 2 diabetes who were poorly controlled by sulfonylurea therapy alone. Diabetes Medicine 13:365-370, 1996
19. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
20. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, Horikoshi H, Kodama T: Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 123:227-234, 1996
21. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta-Pasini A, Davoli A, Rigoni A, Lo-Cascio V: Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40:165-172, 1997
22. Kawai K, Kawasaki-Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T, Yoshioka T, Komai T, Nakamura K: Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47: 356-368, 1997
23. Chung BH, Wilkinson T, Geer JC, Segrest JP: Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 21:284-291, 1980
24. Chait A, Gilmore M, Kawamura M: Inhibition of low-density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha 1-adrenergic antihypertensivc agent. An J Hypertens 7:159-167, 1994
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
26. Langer T, Stober W, Levy RI: The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest 51:1528-1536, 1972
27. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 52:302-310, 1978
28. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jurgens G: A spectrophotometric assay for lipid peroxides in serum lipoprotein using a commercially available reagent. J Lipid Res 30:627-630, 1989
29. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic Res Commun 6:67-75, 1989
30. Esterbauer H, Gebicki J, Puhl J, Jurgens G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341-390, 1992
31. März W, Sickmeier R, Scharnagl H, Seiffert UB, Gross W: Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins. Clin Chem 39:2276-2281, 1993
32. Kirk EA, Moe GL, Caldwell MT, Lemmark JA, Wilson DL, LeBoeuf RC: Hyperand hypo-responsiveness to dietary fat and cholesterol among inbred mice: searching for level and variability genes. J Lipid Res 36:1522-1532, 1995
33. Böyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21:77-99, 1968
34. Bierman EL, Stein O, Stein Y: Lipoprotein uptake and metabolism by rat aortic smooth muscle cells in tissue culture. Circ Res 35:136-150, 1974
35. Rice-Evans C, Miller NJ: Total antioxidant status in plasma and body fluids. Methods Enzymol 234:279-293, 1994
36. Ceriello A, Quatraro A, Giugliano D: New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med 7:297-299, 1992
37. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH: Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 102:63-67, 1993
38. Hunt JV, Smith CC, Wolff SP: Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39: 1420-1424, 1990
39. Smith EB, Slater RS: The microdissection of large atherosclerotic plaques to give morphologically and topographically defined fractions for analysis. Atherosclerosis 15:37-56, 1972
40. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
41. Feingold KR, Grunfeld C. Pang M, Doerrler W, Krauss RM: LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetic. Arterioscler Thromb 12:1496-1502, 1992
42. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 46:433-439, 1997
43. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 26:553-573, 1997
44. Tack CJ, Smits P, Demacker PN, Stalenhoef AF: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796-799, 1998
45. Hirano T, Yoshino G, Kazumi T: Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Interm Med 129:162-163, 1998
46. Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR: Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 37:1038-1047, 1997
47. Nagasaka Y, Kaku K, Nakamura K, Kaneko T: The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low-density lipoprotein in vitro. Biochem Pharmacol 50:1109-1111, 1995
48. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M. Komoda T: Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 235:113-116, 1997
49. Packer JE, Slater TF, Willson RL: Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 278:737-738, 1979